Physician profile
Jing Dong
NPI 1356341119
$6,566.41
in general payments reported to CMS, 2019-2025
27 companies · $825 in 2025
The $825 reported for 2025 was more than what a typical Ophthalmology provider received nationally (typical 2025 total: $384).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $1,338 · 2020: $714 · 2021: $1,029 · 2022: $1,120 · 2023: $980 · 2024: $560 · 2025: $825.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $2,365.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $2,365.38 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Alcon Vision LLC | $1,734.91 | 2019-2025 | Clareon, Rocklatan, Unity |
| Allergan, INC. | $982.84 | 2019-2022 | |
| Sun Pharmaceutical Industries INC. | $535.86 | 2019-2025 | |
| Abbvie INC. | $477.08 | 2022-2025 | Durysta, Vuity, Lumigan |
| Novartis Pharmaceuticals Corporation | $447.03 | 2019-2023 | |
| Glaukos Corporation | $444.12 | 2019-2023 | Photrexa Cross-Linking Kit |
| New World Medical,INC. | $421.05 | 2019-2023 | |
| Oyster Point Pharma, INC. | $300.35 | 2022-2024 | Tyrvaya |
| Notal Vision, INC. | $153.04 | 2022 | |
| Aerie Pharmaceuticals, INC. | $141.28 | 2019-2021 | |
| Bausch & Lomb Americas INC. | $128.09 | 2022-2025 | Xiidra, Miebo |
| Dompe US, INC. | $123.14 | 2021-2025 | Oxervate |
| Bausch & Lomb, A Division of Bausch Health US, LLC | $120.05 | 2019-2021 | |
| Ocular Therapeutix, INC. | $104.06 | 2019-2025 | Dextenza |
| Johnson & Johnson Surgical Vision, INC. | $90.36 | 2023-2025 | Tecnis Iol, Tecnis Iol, Tecnis Simplicity |
Show all 27 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Carl Zeiss Meditec, INC. | $61.30 | 2019 | |
| Sight Sciences, INC. | $50.69 | 2019-2024 | Omni Surgical System |
| Tarsus Pharmaceuticals, INC. | $45.78 | 2024 | Xdemvy |
| Rxsight INC | $38.43 | 2022-2024 | Rxsight Light Delivery Device (Ldd), Rxsight Contact Lens, Rxsight Injector Handpiece |
| Ivantis, INC | $35.33 | 2020-2021 | |
| Kala Pharmaceuticals, INC. | $24.29 | 2021 | |
| Amgen INC. | $22.75 | 2024 | Tepezza |
| Shire North American Group INC | $19.54 | 2019 | |
| Carl Zeiss Meditec Ag | $19.40 | 2020 | |
| Johnson & Johnson Vision Care, INC. | $16.89 | 2019 | |
| Horizon Therapeutics Plc | $14.94 | 2023 | Tepezza |
| Eyepoint US, INC. | $13.81 | 2020 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Jing Dong listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.